Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15796255 | 1.00 | MMP2 (0.42) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13696040 | 0.90 | CHRNB2 (0.47) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL14403910 | 0.87 | MMP2 (0.40) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13672046 | 0.87 | MMP2 (0.40) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22629334 | 0.87 | MMP2 (0.40) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL25286492 | 0.87 | MMP2 (0.40) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13672052 | 0.87 | MMP2 (0.40) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL14403914 | 0.87 | MMP2 (0.40) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL16202720 | 0.81 | MMP2 (0.50) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL27100657 | 0.81 | MMP2 (0.50) | MMP2ANPEPCHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MMP2 52/4885ANPEP 91/4885CHRNB2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.